Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting

May 16, 2019 by Website Admin in

Preliminary results from patients treated with BPX-601 who underwent lymphodepletion with cyclophosphamide plus fludarabine to be presented

Tweet

Share

Pin it

Previous StoryBellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update Next StoryLivaNova to Present at the UBS Global Healthcare Conference